Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AIMT

Aimmune Therapeutics (AIMT) Stock Price, News & Analysis

Aimmune Therapeutics logo

About Aimmune Therapeutics Stock (NASDAQ:AIMT)

Key Stats

Today's Range
$34.49
$34.49
50-Day Range
$34.30
$34.59
52-Week Range
$10.09
$37.00
Volume
N/A
Average Volume
1.71 million shs
Market Capitalization
$2.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Receive AIMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AIMT Stock News Headlines

Aimtron Electronics Ltd (AIMT)
Elon Musk has put himself in their crosshairs
Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
See More Headlines

AIMT Stock Analysis - Frequently Asked Questions

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) posted its earnings results on Thursday, July, 30th. The biotechnology company reported ($1.06) EPS for the quarter, hitting analysts' consensus estimates of ($1.06).

Aimmune Therapeutics (AIMT) raised $124 million in an initial public offering on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Meta Platforms (META), Xtrackers California Municipal Bond ETF (CA) and Bristol-Myers Squibb (BMY).

Company Calendar

Last Earnings
7/30/2020
Today
11/14/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AIMT
Fax
N/A
Employees
228
Year Founded
N/A

Profitability

Net Income
$-248,500,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.66 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.26 billion
Optionable
Optionable
Beta
1.76
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:AIMT) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners